On the Direct Characterization and Quantification of Active Ingredients in Commercial Solid Drugs using PIXE, PIGE and ToF-SIMS techniques



<u>B. Nsouli¹</u>, K. Zahraman¹, A. Bejjani ^{1,4}, M. Roumie¹, E. Fadel², G. younes³, M. Noun¹, F. Yazbi³, J.P. Thomas⁴

Lebanese Atomic Energy Commission- Ion Beam Analysis Laboratory
 Beirut Arab University- Faculty of pharmaceutical Analytical Chemistry
 Mediphar laboratories company- Dbayeh Lebanon
 Institut de Physique Nucleaire de Lyon- Universite Claude Bernard Iyon 1

Content

Introduction

- > Experimental
 - Sample Preparation
 - PIXE/PIGE/ToF-SIMS set up

Results

- -Elemental analysis (PIXE/PIGE)
 - Celecoxib, anti-inflammatory (Celebrex[®], Celex[®], pfeizer[®])
 - Atorvastatin, antihyperlipidymic (Lipitor®, Lipinorm®, Strovas®)
 - Clidinium bromide, anticholinergic
 - trifluoperazine, antipsychotic

Binary drug (fludinium®)

-Molecular analysis (ToF-SIMS)

- Fluphenazine dihydrochloride®
- Fludinium®

> Conclusion & Overview



Introduction





- Active Ingredient (therapeutic molecule)
- Excipients (inactive major role in drug formulation) Carrier system (to ensure the delivery of the A.I to the site of action), Control the time of residence of the A.I, physical stability, drug dissolution, antioxidant, coating material, binder (tablets), desintegrants,...

□ The quantification of active ingredients in drugs is a crucial step in the drug quality control process

Classical and universal wet chemical analytical techniques: LC\MS\MS, UV, Voltametry, etc...

If the A.I contains one or more heteroatom F, S, Cl, Br,...



Elemental IBA (PIXE, PIGE) can be explored



Ability of the TT-PIXE and TT-PIGE for the quantification of heteroatom containing active ingredient in drugs

Potential of the TOF- SIMS for heteroatom free active ingredients quantification

Experimental



• Sample category: capsule, tablet, coated tablet



• Sample preparation for elemental analysis (PIXE-PIGE)

Decapsulating





Decoating



Milling



Pellet with external binder (0.1-0.2g)



Carbon coating Sample/Al sample holder



Experimental

• ToF-SIMS technique * Ar³⁺ 9MeV delivered by the 4MV VDG accelerator of the IPNL



ToF detection with high transmission
 Ion/Ion technique (static mode ~1000-5000 ions/s over ~300 um beam diameter)
 Negative and positive ion mode
 Samples (thin film, pellet, ..)
 Emission of charged characteristic secondary species

Molecular [M+H]⁺





CELECOXIB (F, S)



- Celebrex-pfizer origin A 200mg (A.I ~ 70% 75%)
- Celebrex-pfizer origin B 200mg
- Celex-alpha 100 mg
- Celexocib Standard (A.I = 100%)



Results : Elemental quantification

CELECOXIB (F, S)

Organic matrix : Method validation !! -Stability under beam irradiation -Matrix composition Std and Drugs: Matrix correction?

Stability of the matrix under ion irradiation was checked 3 Mev p+ 0.1 nA-2 nA -10 nA different acquisition time Accumulated charge during the analysis $0.5-5\mu C$ Dose and dose effect assessment M_A .

\rightarrow Count rates of F and S per μ C were practically stable

Matrix similarity of the Std and the analysed drugs was confirmed by RBS

Quantification by relative calculation/external standard without matrix correction

% of Celecoxib in analyzed drug									
	Standard	D	rug A	Dr	rug B	Drug C			
	Celecoxib	labeled	measured	labeled	measured	labeled	measured		
F	100%	72,5%	72% ± 0.5	72,5%	73% ± 0.5	68.9%	$68.2\% \pm 0.5$		
S	100%	72,5%	74.7% ± 0.7	72.5%	74% ± 0,7	68.9%	68% ± 0.7		

TIEMONIUM METHYLSULFATE (S)



- Timozin 50 mg (A.I ~ 16%)

- TIE Standard (A.I. = 100%)

Labeled 50 mg TIE PIXE relative quantification: External Standard 60 mg ± 1.2

Matrix correction (PIXE absolute quantification) 48.7mg ± 1.1

ATORVASTATIN (F)



Storvas 10 mg
Lipinorm 10 mg
Lipitor 10mg

(A.I ~ 6.5%)

ATORVASTATIN (F)



Elemental composition of the Atorvastatin standard (100 % atorvastatin) is significantly <u>different</u> from the composition of the analyzed drug samples (RBS measurements)

Elemental composition %

	C _t	C _m	H	H _m	\mathbf{F}_{t}	- F _m	N _t	N _m	O _t	O _m	Ca _t	Ca _m
Atorvastatin std.	68.61	69.42	5.93	6.00	3.29	3.29	4.85	4.78	13.85	12.82	3.47	3.69
Lipitor®		40.3		6.76		0.25		4.16		35.6		12.9

ATORVASTATIN (F)

$$\frac{Y_{\textit{Samp}}}{Y_{\textit{Ref}}} = \frac{C_{\textit{Samp}}}{C_{\textit{Ref}}} * \frac{S_{\textit{Ref}}(E_{1/2})}{S_{\textit{Samp}}(E_{1/2})}$$



Incident energy

Atorvastatin Active Ingridient (mg)									
Ste	orvas® 10 mg		Lipitor® 10 mg			Lipinorm® 10 mg			
Measured relatively/std	measured with matrix correction	UV	Measured relatively/std	measured with matrix correction	UV	Measured relatively/ std	measured with matrix correction	UV	
12.5±0.3	11.2±0.3	10.9±0.4	11.9±0.3	11.0±0.3	10.8±0.2	12.1±0.2	11.0±0.3	11.0±0.1	

PIGE RESULTS ARE IN A GOOD AGREEMENT WITH UV MEASUREMENTS



FLUDINIUM (Br, S, Cl, F)

Analysed Samples:

-Standards with different % of the two A.I. and excipients. -Fludinium commercial drug with different compositions

Stability under irradiation:

→ Samples are <u>stable</u> under analysis conditions (3MeV, 0.2 nA, 0.1µC,15 min acquisition)
 → Loss of Cl under ion irradiation even under condition of analysis
 → Cl is not related to thev A.I by covalent band it is thermo fragile.

Cl will not considered for quantification S, F: quantification of A.I.2 Br: quantification of A.I.1

FLUDINIUM (Br, S, Cl, F)

VALIDITY OF THE ANALYSIS

S direct quantification in drugs/standard is highly affected by matrix composition of the analyzed drugs. Matrix correction is needed (A.I.2)
 Br can be quantified directly in drugs/standard (A.I 1)
 F can be quantified directly in drugs/standard (A.I 2)



FLUDINIUM (Br, S, Cl, F)

Sample labeled composition	S (matrix correction) PIXE-Gupix	F (direct analysis) PIGE	Br (direct analysis) PIXE
50mg A.I.1, 50mg A.I.2 3.33% S, 5.9% F , 9.25% Br	3.37%±0.16	5.7% ±0.2	9.4% ±0.2
40mg A.I.1, 40mg A.I.2, 20 mg Excipient 2.67% S, 4.7% F, 7.4% Br	2.60%±0.12	4.61% ±0.22	7.47% ±0.22
25mgA.I.1, 25mgA.I.2, 50mg Excipient 1.67% S, 2.97% F, 4.6% Br	1.62%±0.03	2.73% ±0.13	4.66% ±0.14
12.2mg A.I.1, 4.9mgA.I.2, 82.9mg Excipient 0.32% S, 0.58% F, 2.25% Br	0.31%±0.01	0.57% ±0.03	2.26% ±0.07
7.9mg A.I.1, 2.6mg A.I.2, 89.5mg Excipient 0.175% S, 0.31% F, 1.46% Br	0.18%±0.01	0.35% ±0.02	1.53% ±0.04
0.58mg A.I.1, 1.45mg A.I.2, 97.2mg Excipient 388ppm S, 691ppm F, 2692ppm Br	434ppm±43	705ppm±35	2943ppm±147

Results : Molecular analysis (ToF-SIMS)

FIRST APPROACH RESULTS AND DISCUSSION

>Larger number of A.I. are <u>heteroatom free</u>.

Solecular characterization in stead of element analysis

Surface analysis - Semi quantitative

Surface structure)

Results : ToF-SIMS

FLUHENAZINE DIHYDROCHLORIDE



Results : ToF-SIMS

FLUHENAZINE DIHYDROCHLORIDE



Any semi-quantitation needs that the thickness of the sample > secondary ion escape depth

In positive emission semi-quantification can be extracted

γ %

%fluphenazine/ Excipient





Negative emission

Results : ToF-SIMS

FLUDINIUM (BINARY DRUG)

2.5 mg Clidinium Br, 1 mg Trifluoperazine



Conclusion and Overview

- PIXE and PIGE techniques are appropriate for rapid and accurate quantification of A.I. containing heteroatoms like S, F, Cl, Br.
- Methode validation: Ensure the stability of the sample under ion irradiation, -Elemental composition of the standard and the analyzed drugs. – Quantification was validated with or without matrix correction.
- **TOF-SIMS can be promising technique for A.I. heteroatom free characterization**
- Effort to be done in the sample preparation techniques to ensure analytical reproducibility and trueness (ToF-SIMS)
- A.I. determination in liquid form (syrup) to be analyzed as thin film
- Elemental and molecular techniques for analysis of solid drug with several A.I. (>3A.I. with low concentration ppm range)
- TOF-SIMS Exploration of the use of internal standards for direct quantification (dlabeled A.I. or chemically similar molecule(s) to A.I.)

Thank you for you attention